Showing 971-980 of 1211 results for "".
- TFOS Recognizes the Bioprotectant Properties of Trehalose, a Component of Thealoz Duo, in the Treatment of Dry Eyehttps://modernod.com/news/tfos-recognizes-the-bioprotectant-properties-of-trehalose-a-component-of-thealoz-duo-in-the-treatment-of-dry-eye/2480223/The TFOS international Dry Eye WorkShop II (TFOS DEWS II), whose report has been published in the July 2017 issue of the Ocular Surface journal, acknowledged that trehalose is an effective ingredient in association with hyaluronic acid for the tre
- New Collaboration to Produce Opticianry-Focused Educational Panel at OptiCon ’26https://modernod.com/news/new-collaboration-to-produce-opticianry-focused-educational-panel-at-opticon-26/2485385/The Contact Lens Institute (CLI) and the United Opticians Association (UOA) announced a new collaboration to co-produce "Vision for Growth: Consumer Perspectives on Opticianry & Contact Lens Success," an educational panel exclusive to OptiCon ’26 @ Vision Expo.
- Oculus Smartfield Perimeter Launches Aboard the International Space Station to Support Vision Researchhttps://modernod.com/news/oculus-smartfield-perimeter-launches-aboard-the-international-space-station-to-support-vision-research/2484168/Oculus announced that its Smartfield perimeter has successfully launched aboard the International Space Station (ISS) to support research on Spaceflight Associated Neuro-ocular Syndrome (SANS)—a condition known to affect astronauts’ vision during l
- Gore Launches 0.5 mL Silicone-Free Gore Improject Plunger for Ophthalmic Pre-Filled Syringeshttps://modernod.com/news/gore-launches-05-ml-silicone-free-gore-improject-plunger-for-ophthalmic-pre-filled-syringes/2482843/W. L. Gore & Associates announced the commercial launch of the 0.5 mL silicone-free Gore Improject syringe plunger. The new offering, made within the company's PharmBIO business, is designed for prefilled syringes used in various applications, including ophthalmic intr
- Rare Pediatric Disease Designation Granted for Ocugen's Gene Therapy for the Treatment of Stargardt Diseasehttps://modernod.com/news/rare-pediatric-disease-designation-granted-for-ocugens-gene-therapy-for-the-treatment-of-stargardt-disease/2482831/Ocugen announced that the FDA has granted Rare Pediatric Disease Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previously, OCU410ST received Orphan Drug designations
- Genentech: Largest Real-World Studies Show Vabysmo’s Long-Term Benefits for Wet AMD, DMEhttps://modernod.com/news/genentech-largest-real-world-studies-show-vabysmos-long-term-benefits-for-wet-amd-dme/2482798/Genentech presented more than 20 abstracts across its ophthalmology portfolio at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Key studies highlight Vabysmo’s long-term ability to sustain vision improvements in patients with wet
- Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Resultshttps://modernod.com/news/isarna-therapeutics-presents-positive-phase-2-better-trial-final-results-at-arvo-2025/2482797/Isarna Therapeutics presented final positive results from its phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on May 6. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, shared data
- Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-datasets-on-the-potential-of-its-anti-vegf-therapy-dosed-twice-yearly-for-wet-amd/2482790/Valitor announced data from VLTR-559, its long-acting anti-VEGF biologic in development for its wet age-related macular degeneration (AMD) treatment, and its multivalent polymer (MVP) technology platform, were presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annua
- Johnson & Johnson to Present New Scientific Data on Acuvue Oasys Max 1-Day, Tecnis Odyssey, and a Purely Refractive Next Generation EDF IOL at ARVOhttps://modernod.com/news/johnson-johnson-to-present-new-scientific-data-on-acuvue-oasys-max-1-day-tecnis-odyssey-and-a-purely-refractive-next-generation-edf-iol-at-arvo/2482783/Johnson & Johnson will present new data on several of its latest innovations through 35+ posters and oral presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 4-8. New in-vitro methodology shows that Acuvue Oasys Max&nb
- Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVOhttps://modernod.com/news/opus-genetics-announces-presentation-of-opgx-lca5-gene-therapy-data-at-arvo/2482782/Opus Genetics announced 1-year results from adult patients treated in the ongoing phase 1/2 Study of its lead gene therapy candidate OPGx-LCA5. These results were presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), taking place May 4